Comparative Pharmacology
Head-to-head clinical analysis: EXJADE versus JADENU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXJADE versus JADENU.
EXJADE vs JADENU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deferasirox is an oral iron chelator that binds iron with high affinity in a 2:1 ratio. It promotes excretion of iron primarily in the feces via bile, reducing total body iron stores.
Deferasirox is an oral iron chelator that binds trivalent iron (Fe3+) with high affinity, forming a stable complex that is excreted primarily in the feces.
20-40 mg/kg orally once daily, titrated based on serum ferritin trends, maximum 40 mg/kg per day.
30 mg/kg once daily orally, up to a maximum of 60 mg/kg/day, for iron chelation in patients with thalassemia or other chronic iron overload; dose should be adjusted based on serum ferritin levels and therapeutic response.
None Documented
None Documented
Terminal elimination half-life is 8–16 hours, supporting once-daily dosing.
Terminal elimination half-life is 8-16 hours (mean ~12 h) in patients with transfusional iron overload, allowing once-daily dosing.
Primarily fecal (84% of total clearance), with ~8% renal (as unchanged drug and metabolites).
Primarily fecal (hepatobiliary) ~75-90% as unchanged drug and iron complex; renal excretion of deferasirox is minimal (<5% unchanged).
Category C
Category C
Iron Chelator
Iron Chelator